Phase 4 N=65 Randomized Double-blind Treatment

Preemptive Analgesia With Celecoxib for Acute Dental Pain Management

Pain, Postoperative

Bottom Line

View on ClinicalTrials.gov: NCT04790812 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2024

Primary outcome: Primary: Pain as Assessed by a Visual Analogue Scale (VAS) — 4; 2.33 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Celecoxib (Drug); Acetaminophen (Drug); Placebo (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center, Houston
Primary completion: Mar 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
PRIMARY Pain as Assessed by a Visual Analogue Scale (VAS)	1.75; 2.83	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Pain as Assessed by a Categorical Descriptive Questionnaire	0; 0; 2; 1; 0; 0	—
SECONDARY Number of Participants Who Receive an Emergency Analgesic Intervention	0; 0	—

Summary

The purpose of this study is to compare the effect on postoperative pain of a single agent nonsteroidal anti-inflammatory drug (NSAID) [celecoxib plus placebo] to an NSAID combination [celecoxib plus acetaminophen] administered preemptively to patients prior to impacted third molar surgery. .

Eligibility Criteria

Inclusion Criteria

American Society of Anesthesiologists (ASA) physical status classification 1 or 2
at least 1 impacted mandibular third molar planned for extraction

Exclusion Criteria

ASA 3 or higher for physical status classification
severe pericoronitis associated with third molar to be extracted
any known allergies to NSAIDs, aspirin, acetaminophen, sulfa drugs
history of cardiovascular or cerebrovascular disease
hepatic disease or impairment
pregnancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04790812). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.